Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytokinetics
(NQ:
CYTK
)
52.61
-0.02 (-0.04%)
Streaming Delayed Price
Updated: 3:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cytokinetics
< Previous
1
2
3
4
5
6
7
Next >
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
Where Cytokinetics Stands With Analysts
October 11, 2022
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Cytokinetics
July 15, 2022
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306%
October 03, 2022
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...
Via
Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
September 07, 2022
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
Via
Benzinga
Where Cytokinetics Stands With Analysts
May 24, 2022
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Via
Benzinga
Cytokinetics Posts Cohort 3 Data From Aficamten Trial In Heart Disease Patients
February 01, 2022
Cytokinetics Incorporated (NASDAQ: CYTK) has announced
Via
Benzinga
Swing Trading Stock Watchlist For The Week Of Sept. 6
September 04, 2022
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look.
Via
Talk Markets
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
August 05, 2022
Analysts have provided the following ratings for Cytokinetics (NASDAQ:CYTK) within the last quarter:
Via
Benzinga
Cytokinetics Records $89M Q2 Sales On Deferred Mavacamten Revenues, Forecasts FY22 Cash Of Over $800M
August 05, 2022
Via
Benzinga
Recap: Cytokinetics Q2 Earnings
August 04, 2022
Cytokinetics (NASDAQ:CYTK) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics beat estimated...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 30, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 29, 2022
Gainers
Via
Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 5 Analyst Ratings Have To Say About Cytokinetics
June 10, 2022
Within the last quarter, Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings:
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
May 22, 2022
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...
Via
Talk Markets
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Biggest Price Target Changes For Monday
May 16, 2022
Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.
Via
Benzinga
Cytokinetics: Q1 Earnings Insights
May 04, 2022
Cytokinetics (NASDAQ:CYTK) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cytokinetics missed estimated...
Via
Benzinga
70 Biggest Movers From Friday
May 02, 2022
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)...
Via
Benzinga
48 Stocks Moving In Friday's Mid-Day Session
April 29, 2022
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:...
Via
Benzinga
Cytokinetics's Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients
April 04, 2022
Via
Benzinga
Cytokinetics: Q4 Earnings Insights
February 24, 2022
Cytokinetics (NASDAQ:CYTK) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
33 Stocks Moving In Friday's Mid-Day Session
January 07, 2022
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 35.9% to $4.6899 after the company announced an integration with Amazon Ads' demand-side platform. Absci...
Via
Benzinga
56 Biggest Movers From Friday
January 10, 2022
Gainers Hour Loop, Inc. (NASDAQ: HOUR) shares jumped 99.8% to $7.99 after the company priced its IPO at $4 per share. China HGS Real Estate Inc. (NASDAQ: HGSH) shares...
Via
Benzinga
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
December 26, 2021
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.